OBT and Boehringer Ingelheim (BI) have been collaborating since 2013. Our initial collaboration yielded two partnered clinical products and based on this success we entered into a second collaboration in Q4 2020. Our 2020 collaboration has already yielded a program for which BI has exercised an exclusive option.
Through this collaboration, OBT will validate up to five novel oncology drug targets, previous identified using OBT's OGAP® discovery platform, and generate antibodies against them. Kite, a Gilead Company, will have the exclusive right to develop and commercialize therapies based on these targets and antibodies.